Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial
Publication Details
Frontiers in Pediatrics
September 2024
Author(s)
Yaacov Frishberg1, Wesley Hayes2, Hadas Shasha-Lavsky 3 4, David J Sas5, Mini Michael6, Anne-Laure Sellier-Leclerc7, Julien Hogan8, Richard Willey9, John M Gansner10, Daniella Magen11
Affiliations
1Division of Pediatric Nephrology, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; 2Department of Paediatric Nephrology, Great Ormond Street Hospital, London, United Kingdom; 3Pediatric Nephrology Unit, Galilee Medical Center, Nahariya, Israel; 4Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel; 5Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States; 6Division of Pediatric Nephrology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, United States; 7Hôpital Femme Mère Enfant and Centre d'Investigation Clinique Inserm, Hospices Civils de Lyon, ERKnet, Bron, France; 8Pediatric Nephrology Department, Hôpital Robert-Debré, APHP, Paris, France; 9Biostatistics, Alnylam Pharmaceuticals, Cambridge, MA, United States; 10Clinical Development, Alnylam Pharmaceuticals, Cambridge, MA, United States; 11Pediatric Nephrology Institute, Rambam Health Care Campus, and Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
Abstract
Background:
Primary hyperoxaluria type 1 (PH1) is a genetic disorder resulting in overproduction of hepatic oxalate, potentially leading to recurrent kidney stones, nephrocalcinosis, chronic kidney disease, and kidney failure. Lumasiran, the first RNA interference therapeutic approved for infants and young children, is a liver-directed treatment that reduces hepatic oxalate production. Lumasiran demonstrated sustained efficacy with an acceptable safety profile over 12 months in infants and young children (age <6 years) with PH1 in ILLUMINATE-B (clinicaltrials.gov: NCT03905694), an ongoing, Phase 3, multinational, open-label, single-arm study.
Methods:
Here, we report interim efficacy and safety findings from ILLUMINATE-B following 30 months of lumasiran treatment. Eligible patients had an estimated glomerular filtration rate (eGFR) >45 ml/min/1.73 m2 if ≥12 months old or normal serum creatinine if <12 months old, and a urinary oxalate to creatinine ratio (UOx:Cr) greater than the upper limit of normal. All 18 patients enrolled in ILLUMINATE-B completed the 6-month primary analysis period, entered an extension period of up to 54 months, and continue to participate in the study.
Results:
At Month 30, mean percent change from baseline in spot UOx:Cr was −76%, and mean percent change in plasma oxalate was −42%. eGFR remained stable through Month 30. In 14 patients (86%) with nephrocalcinosis at baseline, nephrocalcinosis grade improved at Month 24 in 12; no patient worsened. In the 4 patients without baseline nephrocalcinosis, nephrocalcinosis was absent at Month 24. Kidney stone event rates were ≤0.25 per person-year through Month 30. Mild, transient injection site reactions were the most common lumasiran-related adverse events (17% of patients).
Conclusions:
In infants and young children with PH1, long-term lumasiran treatment resulted in sustained reductions in urinary and plasma oxalate that were sustained for 30 months, with an acceptable safety profile. Kidney function remained stable, low kidney stone event rates were observed through Month 30, and nephrocalcinosis grade improvements were observed through Month 24.
PMID
39355649
DOI
10.3389/fped.2024.1392644
Publication Materials
Visit website/URL/link
Manuscript
